ERBB2 and breast cancer: This nuance emphasizing a ‘lack of overexpression’ rather than an ‘absence of HER2’ is becoming significant, as around 50% of cases previously considered HER2-BC fall now into the ‘HER2low’ category, including many TNBC cases [3,4].